- Global Pharma News & Resources

Formycon and Leukocare cooperate in the development of high-quality biopharmaceuticals

DGAP-News: Formycon AG / Key word(s): Alliance/Miscellaneous
24.03.2021 / 07:30
The issuer is solely responsible for the content of this announcement.


Press Release // March 24, 2021

Formycon and Leukocare cooperate in the development of high-quality biopharmaceuticals

- Companies combine leading development expertise in high-quality biopharmaceuticals with profound knowhow in biopharmaceutical formulation development

- Master Service Agreement stipulates potential development of stable Leukocare formulations for additional Formycon projects in upcoming years

- First project covers formulation development for a biosimilar of a blockbuster therapeutic antibody

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and Leukocare AG today announced a collaboration in the area of high-quality biopharmaceuticals. Under the terms of this agreement, Leukocare will apply its formulation development technologies combining state-of-the art protein analytics, bioinformatics and artificial intelligence to develop stable formulations potentially for several candidates in Formycon's product pipeline. The first project has been started and covers the formulation development for a biosimilar of a blockbuster therapeutic antibody.

By applying Leukocare's formulation and bioinformatics expertise to Formycon's comprehensive development knowhow, the partners want to achieve superior stability profiles overall leading to additional value propositions for development projects.

Stefan Glombitza, Chief Operating Officer at Formycon, stated, "Suitable Drug Product formulations are an essential success factor in the development of biopharmaceutical drugs and are getting increasingly important in the competitive IP landscape. We are convinced that Leukocare's technology platform can successfully complement our development expertise and look very much forward to our collaboration."

"Michael Scholl, Chief Executive Officer at Leukocare, commented, "We are very proud of this partnership with Formycon, a world-leading developer of high-quality biosimilars and biopharmaceuticals. This collaboration is a perfect fit for both companies to drive the development of high-quality products."

"Andreas Seidl, Chief Operating Officer at Leukocare, added, "Our algorithm-based formulation development expertise will allow Formycon to make use of a large formulation design space, thereby gaining manifold options for freedom to operate in a competitive environment. This will strongly support Formycon in providing high-quality medicines to as many patients as possible."

About Formycon:
Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 fusion protein.

About Leukocare:
Leukocare AG, located in Martinsried/Munich, Germany, is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence. The formulation development approach consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and a rational development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product's needs. Leukocare's superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

Contact Formycon AG:
Sabrina Müller
Senior Manager Corporate Communications and Investor Relations
Fraunhoferstr. 15
82152 Martinsried/Planegg/Germany
Phone.: +49 (0) 89 - 86 46 67 149
Fax + 49 (0) 89 - 86 46 67 110

Contact Leukocare AG:
Dr. Andreas Seidl (COO) / Rebekka Ströver (Specialist Communications & Marketing)
Am Klopferspitz 19
82152 Planegg
Phone: +49 (0) 89 - 7801 665 0 / Tel.: +49 (0) 89 - 7801 665 14 /

This press release may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.

24.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Phone: 089 864667 100
Fax: 089 864667 110
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1177773

End of News DGAP News Service

Editor Details

Last Updated: 24-Mar-2021